scholarly journals Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view

2021 ◽  
Author(s):  
Ludek Berec ◽  
Martin Smid ◽  
Lenka Pribylova ◽  
Ondrej Majek ◽  
Tomas Pavlik ◽  
...  
Keyword(s):  
Czech Republic ◽  
Hospital Admission ◽  
Booster Dose ◽  
Hospital Admissions ◽  
Real Life ◽  
Vaccine Effectiveness ◽  
The Czech Republic ◽  
Vaccine Type ◽  
Previous Infection ◽  
Over Time

Background. Evidence is accumulating that the effectiveness of covid-19 vaccines against infection wanes, reaching relatively low values after 6 months. Published studies demonstrating this effect based their findings on a limited range of vaccines or subset of populations, and did not include booster vaccine doses or immunity obtained due to covid-19 infection. Here we evaluate effectiveness of covid-19 vaccines, booster doses or previous infection against covid-19 infection, hospital admission or death for the whole population in the Czech Republic. Methods. Data used in this study cover the whole population of the Czech Republic reported as infected and/or vaccinated between the first detected case on March 1, 2020 and November 20, 2021 (for reinfections), or December 26, 2020 and November 20, 2021 (for vaccinations), including hospital admissions and deaths. Vaccinations by all vaccines approved in the EU were included in this study. Anonymous, individual-level data including dates of vaccination, infection, hospital admission and death were provided by the the Institute of Health Information and Statistics of the Czech Republic. The risks of reinfection, breakthrough infection after vaccination, hospital admission and death were calculated using hazard ratios from a Cox regression adjusted for sex, age, vaccine type and vaccination status. Findings. The vaccine effectiveness against any PCR-confirmed infection declined from 87% (95% CI 86-87) at 0-2 months after the second dose to 53% (95% CI 52-54) at 7-8 months for Comirnaty, from 90% (95% CI 89-91) at 0-2 monthsto 65% (95% CI 63-67) at 7-8 months for Spikevax, and from 83% (95% CI 80-85) at 0-2 months to 55% at (95% CI 54-56) 5-6 months for the Vaxzevria. For Janssen Covid-19 Vaccine we found no significant decline but the estimates are less certain. The vaccine effectiveness against hospital admissions and deaths decayed at a significantly lower rate with about 15%, resp. 10% decline during the first 6-8 months. The administration of a booster dose returns the protection to or above the estimates in the first two months after dose 2. In unvaccinated but previously SARS-CoV-2-positive individuals the protection against PCR-confirmed SARS-CoV-2 infection declined from close to 97% (95% CI 97-97) after 2 months through 90% at 6 months down to 72% (95% CI 65-78) at 18 months. Interpretation. Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospital admission and death. A booster dose is shown to restore the vaccine effectiveness back to the levels seen soon after the completion of the basic vaccination schedule. The post-infection immunity decreases over time, too. Funding. No external funding was used to conduct this study.

scholarly journals Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

BMJ ◽  
2021 ◽  
pp. n1943 ◽  
Author(s):  
Hannah Chung ◽  
Siyi He ◽  
Sharifa Nasreen ◽  
Maria E Sundaram ◽  
Sarah A Buchan ◽  
...  
Keyword(s):  
Hospital Admission ◽  
Clinical Characteristics ◽  
Hospital Admissions ◽  
Vaccine Effectiveness ◽  
Community Dwelling ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Design Study ◽  
Symptomatic Infection ◽  
Polymerase Chain

AbstractObjectiveTo estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).DesignTest negative design study.SettingOntario, Canada between 14 December 2020 and 19 April 2021.Participants324 033 community dwelling people aged ≥16 years who had symptoms of covid-19 and were tested for SARS-CoV-2.InterventionsBNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine.Main outcome measuresLaboratory confirmed SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and hospital admissions and deaths associated with SARS-CoV-2 infection. Multivariable logistic regression was adjusted for personal and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine effectiveness against symptomatic infection and severe outcomes.ResultsOf 324 033 people with symptoms, 53 270 (16.4%) were positive for SARS-CoV-2 and 21 272 (6.6%) received at least one dose of vaccine. Among participants who tested positive, 2479 (4.7%) were admitted to hospital or died. Vaccine effectiveness against symptomatic infection observed ≥14 days after one dose was 60% (95% confidence interval 57% to 64%), increasing from 48% (41% to 54%) at 14-20 days after one dose to 71% (63% to 78%) at 35-41 days. Vaccine effectiveness observed ≥7 days after two doses was 91% (89% to 93%). Vaccine effectiveness against hospital admission or death observed ≥14 days after one dose was 70% (60% to 77%), increasing from 62% (44% to 75%) at 14-20 days to 91% (73% to 97%) at ≥35 days, whereas vaccine effectiveness observed ≥7 days after two doses was 98% (88% to 100%). For adults aged ≥70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days. After two doses, high vaccine effectiveness was observed against variants with the E484K mutation.ConclusionsTwo doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed to be lower, particularly for older adults shortly after the first dose.

Plant poisonings in children in the Czech Republic, 1996-2001

2003 ◽  
Vol 22 (9) ◽  
pp. 467-472 ◽  
Author(s):  
Petra Vichova ◽  
Ludek Jahodar
Keyword(s):  
Czech Republic ◽  
Medical Records ◽  
Hospital Admissions ◽  
Age Groups ◽  
Complete Data ◽  
University Hospital ◽  
The Czech Republic ◽  
Thorn Apple ◽  
And Gender ◽  
Poisoning In Children

Ingestion of or exposure to potentially poisonous plants is a relatively common presenting complaint in hospital paediatric departments, especially amongst toddlers. We present a retrospective study conducted to review the hospital admissions following acute childhood poisoning with plants in the Czech Republic over a 6-year period from 1996 to 2001. Six university hospital paediatric departments and two local hospital paediatric departments were involved in the study. Information and complete data on the cases were collected on the basis of all hospital medical records and internal hospital database outcomes. A total of 174 plant exposures were analysed to tabulate the list of top species involved in plant poisonings. The aims were to provide classification according to agent frequency, clinical presentations, severity of symptoms expressed, affected age groups and gender of patients and to evaluate the treatment according to patient outcome. The most frequent ingestions were of thorn apple seeds (14.9%), followed by dumb cane exposures (11.5%) and common yew (9.8%). Thorn apple, dumb cane, golden chain and raw beans caused the most serious symptoms. There were no fatalities reported out of the reviewed medical records. Complete data on plant poisoning in children from all over the territory of the Czech Republic are not available; however, we believe that the frequency of causes and the rank of plant species commonly involved are properly reflected in our study.

Blackout 2014 Exercise – Prague, the Capital of the Czech Republic

2015 ◽  
Vol 10 (2) ◽  
pp. 270-275 ◽  
Author(s):  
Tomas Hudecek ◽  
◽  
Josef Juránek ◽  
Jaroslav Pejcoch ◽  
◽  
...  
Keyword(s):  
Information Technology ◽  
Czech Republic ◽  
City Management ◽  
The Czech Republic ◽  
Advantages And Disadvantages ◽  
Rule Of Life ◽  
Analysis Of Results ◽  
Potential Damage ◽  
Over Time

As our world becomes increasingly complex over time, we are using increasingly sophisticated tools to be fed and entertained. This increasing complexity has both advantages and disadvantages. Our dependence on electric power is almost absolute and a long-term blackout could become potentially fatal to any region or country hit by it. It has been a rule of life that the intensive preparation to some crisis begins not sooner than after it strikes and causes a big damage. Prague city management did not want to wait to find out, however, and organized an exercise to understand just what such a situation might look like and just how well prepared the capital of the Czech Republic was to manage it. The exercise was designed, run and documented by up-to-date information technology, enabling further study and analysis of results to improve the city’s resilience and to prepare adequate means for mitigating potential damage.

scholarly journals Tożsamość młodzieży wietnamskiego pochodzenia w Republice Czeskiej

1970 ◽  
Vol 44 ◽  
pp. 151-164
Author(s):  
Tomasz Kasprzak
Keyword(s):  
Czech Republic ◽  
Social Consciousness ◽  
Modern World ◽  
Self Awareness ◽  
Social Phenomenon ◽  
The Czech Republic ◽  
Social Transformations ◽  
Continuous Creation ◽  
Over Time

The article presents an image of the identity of young Vietnamese living in the Czech Republic. After the dissolution of Czechoslovakia, most of the Vietnamese were left, and over time this minority started to grow (now they number more than 57,000 people). Multivariate social transformations, manifested in the continuous creation of the modern world, contribute to the difficulty of capturing and unambiguously identifying the notion of identity. Identity is primarily a social phenomenon, is closely related to values accepted in a given society, is present in its culture, and is strongly rooted in social consciousness. Multidimensional and multidimensional identity undoubtedly shapes the problem of self-awareness among Vietnamese youth.

scholarly journals Effectiveness of 2 Influenza Vaccines in Nationwide Cohorts of Finnish 2-Year-Old Children in the Seasons 2015–2016 Through 2017–2018

2020 ◽  
Vol 71 (8) ◽  
pp. e255-e261
Author(s):  
Ulrike Baum ◽  
Sangita Kulathinal ◽  
Kari Auranen ◽  
Hanna Nohynek
Keyword(s):  
Influenza Vaccine ◽  
Virus Type ◽  
Real Life ◽  
Vaccine Effectiveness ◽  
Influenza Vaccines ◽  
Type B ◽  
Live Attenuated Influenza Vaccine ◽  
Vaccine Type ◽  
Decision Making Processes ◽  
Study Population

Abstract Background From 2015–2016 through 2017–2018, injectable, trivalent inactivated influenza vaccines (IIV3) and a nasal spray, tetravalent live-attenuated influenza vaccine (LAIV4) were used in parallel in Finland. To understand how well vaccination with each vaccine type protected children against influenza under real-life conditions, vaccine effectiveness in 2-year-olds was estimated for all 3 seasons. Methods Each season, a nationwide register-based cohort study was conducted. The study population comprised 60 088, 60 860, and 60 345 children in 2015–2016, 2016–2017, and 2017–2018, respectively. Laboratory-confirmed influenza was the study outcome. Seasonal influenza vaccination with either LAIV4 or IIV3 was the time-dependent exposure of interest. Vaccine effectiveness was defined as 1 minus the hazard ratio comparing vaccinated with unvaccinated children. Results From 2015–2016 through 2017–2018, the effectiveness of LAIV4 against influenza of any virus type was estimated at 54.2% (95% confidence interval, 32.2–69.0%), 20.3% (−12.7%, 43.6%), and 30.5% (10.9–45.9%); the corresponding effectiveness of IIV3 was 77.2% (48.9–89.8%), 24.5% (−29.8%, 56.1%), and −20.1% (−61.5%, 10.7%). Neither influenza vaccine clearly excelled in protecting children. The LAIV4 effectiveness against type B was greater than against type A and greater than the IIV3 effectiveness against type B. Conclusions To understand how influenza vaccines could be improved, vaccine effectiveness must be analyzed by vaccine and virus type. Effectiveness estimates also expressing overall protection levels are needed to guide individual and programmatic decision-making processes. Supported by this analysis, the vaccination program in Finland now recommends LAIV4 and injectable, tetravalent inactivated influenza vaccines replacing IIV3.

scholarly journals Analysis of economic risk in potatoes cultivation

2019 ◽  
Vol 65 (No. 7) ◽  
pp. 331-339
Author(s):  
Milan Cizek ◽  
Miroslav Mimra ◽  
Miroslav Kavka ◽  
Jaroslav Humpal
Keyword(s):  
Monte Carlo ◽  
Czech Republic ◽  
Statistical Data ◽  
Simulation Method ◽  
Considerable Variability ◽  
Natural Conditions ◽  
The Czech Republic ◽  
Climate Conditions ◽  
Over Time ◽  
Starch Production

A number of variables influences potatoes growing, including natural conditions, used growing technologies and market conditions. The most important parameters for the production of potatoes crops are yield, farmer’s price, subsidies and costs. All these parameters can change over time. This means that managers of farms must constantly assess the key parameters affecting the economic outturn and analyse the degree of risk of their  achievement. This article analyses the economic risks of potatoes cultivation based on statistical data obtained over the last 10 years. The Monte Carlo stochastic simulation method was used to analyse the risk of gross profits. The results of the calculations confirmed the considerable variability and risk of growing potatoes in the climate conditions of the Czech Republic in general, and especially regarding the first early potatoes and potatoes for starch production.

scholarly journals Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

2019 ◽  
Author(s):  
Peter Grell ◽  
Josef Dvorak ◽  
Michal Vocka ◽  
Stanislav John ◽  
Helena Pitauerova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Czech Republic ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Scoring System ◽  
Risk Group ◽  
Real Life ◽  
The Czech Republic ◽  
Factors Associated

Abstract Background: Trifluridine/tipiracil (TAS-102) is effective in refractory metastatic colorectal cancer (mCRC). Currently, no predictive biomarkers are established and used in clinical practice. Methods: We analyzed data of 160 patients treated with TAS-102 in real clinical practice in the Czech Republic. Different factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Median PFS was 3.3 months, and median OS 10.2 months. Factors significantly associated with PFS and/or OS were: ECOG performance status (PS), time from diagnosis of mCRC > 24 months, initiation of treatment > 3 months from last fluoropyrimidine, number of metastatic sites, baseline CRP level, WBC count, neutrophils count, monocytes count, neutrophil to lymphocyte ratio, development of neutropenia, thrombocytopenia, diarrhea, required dose reduction and cycle delay. We developed a scoring system TAScore from factors available at the beginning of treatment. One point each was assigned to the following factors (PS, diagnosis of mCRC > 24 months, initiation of TAS-102 > 3 months from fluoropyrimidine, baseline CRP, WBC, monocytes count < 0.5 × 10 9 /L) and patients were divided into 3 groups: high risk group (0 to 1 point), intermediate (2 to 3), favorable with 4 or more points. OS according to risk group was: 5.7 months for high risk, 8.7 for intermediate, 12.8 for favorable (P < 0.001). TAScore was also associated with PFS (P < 0.001). Conclusions : TAS-102 is effective in patients with refractory mCRC. We propose simple scoring system TAScore to help with precise patient selection at the beginning of TAS-102 treatment.

scholarly journals Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study.

2021 ◽  
Author(s):  
Glenda E Gray ◽  
Shirley COLLIE ◽  
Nigel Garrett ◽  
Ameena Goga ◽  
Jared Champion ◽  
...  
Keyword(s):  
South Africa ◽  
Health Care ◽  
Health Care Workers ◽  
Booster Dose ◽  
Hospital Admissions ◽  
Vaccine Effectiveness ◽  
Care Organization ◽  
African Health ◽  
Care Workers ◽  
Vaccine Booster

Following the results of the ENSEMBLE 2 study, which demonstrated improved vaccine efficacy of a two-dose regimen of Ad26.COV.2 vaccine given 2 months apart, we expanded the Sisonke study which had provided single dose Ad26.COV.2 vaccine to almost 500 000 health care workers (HCW) in South Africa to include a booster dose of the Ad26.COV.2. Sisonke 2 enrolled 227 310 HCW from the 8 November to the 17 December 2021. Enrolment commenced before the onset of the Omicron driven fourth wave in South Africa affording us an opportunity to evaluate early VE in preventing hospital admissions of a homologous boost of the Ad26.COV.2 vaccine given 6-9 months after the initial vaccination in HCW. We estimated vaccine effectiveness (VE) of the Ad26.COV2.S vaccine booster in 69 092 HCW as compared to unvaccinated individuals enrolled in the same managed care organization using a test negative design. We compared VE against COVID19 admission for omicron during the period 15 November to 20 December 2021. After adjusting for confounders, we observed that VE for hospitalisation increased over time since booster dose, from 63% (95%CI 31-81%); to 84% (95% CI 67-92%) and then 85% (95% CI: 54-95%), 0-13 days, 14-27 days, and 1-2 months post-boost. We provide the first evidence of the effectiveness of a homologous Ad26.COV.2 vaccine boost given 6-9 months after the initial single vaccination series during a period of omicron variant circulation. This data is important given the increased reliance on the Ad26.COV.2 vaccine in Africa.

Sign in / Sign up

Export Citation Format

Share Document